For clinicians
Expert talks
Last updated November 17, 2026
YouTube talks play on this page. UroToday, BCAN, and other sources open from a linked card, with the speakers, source, and date. Within each group, talks are ordered by date.
Genitourinary
27 videos
Bladder
UroToday · Sep 29, 2026
Clinical Decision-Making with ctDNA in Bladder Cancer Practice
Andrea Apolo, Seth Lerner, Jeffrey Ross
Lerner, Apolo, and Ross discuss how they currently use plasma ctDNA and urine tumor DNA in practice, including around cystectomy and in metastatic disease, and where they do not yet change therapy based on a result alone.
Grand Rounds in Urology · Jun 12, 2026
Adjuvant Therapy for Muscle-Invasive Urothelial Carcinoma
Guru P. Sonpavde
Sonpavde reviews adjuvant immunotherapy trials in MIBC and UTUC, including ctDNA analyses from IMvigor010 and CheckMate 274 and the prospective IMvigor011 and MODERN strategies.
VJOncology · Jun 8, 2026
ctDNA monitoring & outcomes in bladder cancer treated with EV & pembrolizumab
Vadim Koshkin
Koshkin discusses a multicenter real-world analysis of longitudinal ctDNA dynamics and outcomes in locally advanced or metastatic urothelial carcinoma treated with enfortumab vedotin plus pembrolizumab.
Personalis, Inc. · Mar 31, 2026 · 3:07
ASCO GU 2026: Bladder Cancer
Alan Tan, Mehmet Murat Zerey
Preliminary real-world results of ultrasensitive whole-genome ctDNA clearance as a biomarker with enfortumab vedotin plus pembrolizumab
Posted by Personalis, Inc..
UroToday · Mar 12, 2026
IMvigor011 Explores ctDNA Dynamics in Adjuvant Therapy for Urothelial Cancer
Thomas Powles, Tian Zhang
Powles discusses IMvigor011 with Tian Zhang, covering ctDNA-positive randomization to atezolizumab versus placebo, MTM as a continuous prognostic measure, and timing of ctDNA clearance.
ecancer · Feb 5, 2026
ctDNA test guides post-surgical immunotherapy for muscle-invasive bladder cancer
Joaquim Bellmunt
Bellmunt reviews IMvigor010’s retrospective ctDNA findings and the prospective IMvigor011 design and disease-free and overall survival results with adjuvant atezolizumab in ctDNA-positive MIBC.
BackTable Tumor Board · Jan 27, 2026 · 57:34
Urothelial Carcinoma: Understanding CTDNA & Precision Medicine w/ Drs. Nizam & McGregor | BackTable Tumor Board Ep. 45
Alan Tan, Amanda Nizam, Brad McGregor
ctDNA in assessing recurrence risk and tailoring perioperative therapy in urothelial carcinoma
UroToday · Jan 14, 2026
Analysis of ctDNA in IMvigor011 Informs Adjuvant Therapy Decisions for Muscle-Invasive Bladder Cancer
Matthew D. Galsky, Sam S. Chang
Galsky reviews IMvigor011 with Sam Chang, including ctDNA-guided adjuvant atezolizumab after cystectomy, conversion during surveillance, and limits of a single negative test.
Bladder Cancer Advocacy Network (BCAN) · Dec 1, 2025
Understanding ctDNA Testing in Bladder Cancer: What It Means for You
Matthew D. Galsky
Patient-facing BCAN webinar in which Galsky explains what ctDNA testing can and cannot show for detection, treatment monitoring, and recurrence surveillance in bladder cancer.
OncoAlert 360 · Oct 29, 2025
IMvigor011 in Bladder Cancer Presented by Dr. Tom Powles at ESMO 2025 from the Podium to you
Thomas Powles
Short recap of Powles’ ESMO 2025 IMvigor011 presentation on ctDNA-guided adjuvant immunotherapy after cystectomy, contemporaneous with the NEJM publication.
UroToday · May 17, 2025
ctDNA in Bladder Cancer: Prognostic Value and Ongoing Clinical Trials
Jonathan Rosenberg, Petros Grivas, Ashish Kamat
Rosenberg and Grivas review the prognostic association of post-cystectomy ctDNA with relapse and distinguish that from still-pending predictive utility pending prospective trials.
UroToday · Jun 27, 2023
The Potential Influence of Circulating Tumor DNA in Treatment Decisions for Bladder Cancer
Petros Grivas, Ashish Kamat
Grivas discusses with Kamat how ctDNA might inform MRD assessment, genomic profiling, and treatment timing in bladder cancer, citing then-available study data.
UroToday · Apr 19, 2022
The Role of ctDNA in Metastatic Urothelial Cancer
Alexander Wyatt, Ashish Kamat
Wyatt discusses ctDNA for residual-disease detection and therapy monitoring in metastatic urothelial carcinoma, including prognostic associations and assay limitations.
European Association of Urology · Nov 29, 2021
Circulating tumour DNA for decision making in high risk and metastatic bladder cancer
Lars Dyrskjøt
EMUC21 interview in which Dyrskjøt explains what ctDNA is and discusses next steps for ctDNA-based treatment decisions in high-risk and metastatic bladder cancer.
UroToday · Jan 27, 2021
Circulating Tumor DNA - Guiding Treatment Decisions in Bladder Cancer
Lars Dyrskjøt, Ashish Kamat
Longer Kamat interview covering Dyrskjøt and the Aarhus group’s work on ctDNA for residual-disease detection, treatment monitoring, and the TOMBOLA trial concept.
UroToday · Oct 16, 2019
Circulating Tumor DNA in Urothelial Cancer
Bishoy M. Faltas, Charles J. Ryan
Early discussion of using circulating tumor DNA to monitor clonal evolution and disease change in urothelial cancer. Older interview; included because Faltas was a requested speaker.
Kidney
Dana-Farber Cancer Institute · Jul 1, 2026
KEYNOTE-564 ctDNA
Toni K. Choueiri
Choueiri reviews the KEYNOTE-564 adjuvant pembrolizumab ctDNA analysis, including the association of ctDNA positivity with worse disease-free outcomes and the assay’s low sensitivity.
GU Oncology Now · Jun 2, 2026
KEYNOTE-564: ctDNA Analysis in Participants Treated With Adjuvant Pembrolizumab
David F. McDermott
McDermott discusses the KEYNOTE-564 ctDNA analysis, limited assay sensitivity, and how improved assays might later help select adjuvant therapy or monitor recurrence risk in RCC.
Personalis, Inc. · Apr 1, 2026 · 5:07
ASCO GU 2026: Kidney Cancer (RCC)
Paulo Siqueira Amaral, Alan Tan
Ultrasensitive whole-genome ctDNA to evaluate recurrence risk after nephrectomy; detections ahead of radiographic recurrence
Posted by Personalis, Inc..
UroToday · Mar 13, 2026
K-COMPASS Study Investigates ctDNA and KIM-1 in Oligometastatic Kidney Cancer
Chad Tang, Leslie Ballas
Tang presents the K-COMPASS model combining ctDNA, KIM-1, and clinical factors to estimate systemic-therapy-free survival after metastasis-directed radiation in oligometastatic clear-cell RCC.
Prostate
UroToday · Oct 31, 2025
ctDNA as an Early Response Signal in RLT and mCRPC Care
Alexander Wyatt, A. Oliver Sartor
Wyatt discusses with Sartor how quantitative ctDNA can complement HRR genomic testing, including as a baseline and early-response marker in radiopharmaceutical trials for mCRPC.
UroToday · Jan 27, 2023
ctDNA: A New Window into Prostate Cancer's Progression and Chronology of Treatment-Resistance
Alexander Wyatt, Charles J. Ryan
Wyatt reviews his group’s Nature work on using ctDNA populations to track prostate-cancer progression and treatment-resistance chronology, including AR-pathway alterations.
Upper tract
GU Oncology Now · Mar 11, 2024
ctDNA to Identify Muscle-Invasive, Non–Organ-Confined UTUC
Roger Li
Li (Moffitt) discusses plasma ctDNA as a potential marker of muscle-invasive or non-organ-confined upper-tract urothelial carcinoma and its prognostic associations.
Germ cell
OncLive · May 18, 2026
Challenges and Future Directions in ctDNA-Guided Care
Pooja Ghatalia, Steven Seyedin, Arnab Basu, Jean Hoffmann-Censits, Noah Richardson
Panel segment on liquid biopsy in testicular cancer, including ctDNA and miRNA-371 for risk stratification and decisions about adjuvant therapy or residual masses. Part of a broader GU ctDNA series.
Across GU
BackTable Tumor Board · Aug 11, 2026 · 28:17
GU Oncology: ASCO Highlights and Impacts on Practice w/ Dr. Alan Tan | BackTable Tumor Board Ep. 76
Alan Tan, Katy Beckermann
Targeted Oncology (Oncology Brothers) · Jun 20, 2024
The Role of ctDNA in Genitourinary Cancer
Toni K. Choueiri
Choueiri and the Oncology Brothers discuss current uses and limits of ctDNA across genitourinary cancers, rather than a single trial readout.